Amgen

Amgen

Biotech company creating biologic medicines

Cardiovascular Key Account Manager

Full-TimeUpdated on 9/30/2026
$159.5k - $215.8k/yr
Mid, Senior
Bachelor's, Master's, PhD
Greenville, SC, USA+2 more

More locations: Charleston, SC, USA | Columbia, SC, USA

Remote

Field-based territory covering Charleston, Greenville, and Columbia, South Carolina.

About the job

Requirements
  • Doctorate degree and 2 years of sales experience and/or related account management experience, or master's degree and 4 years of sales experience and/or related account management experience, or bachelor's degree and 6 years of sales experience and/or related account management experience.
  • Ability to understand and identify key staff and departments that influence decision-making for biopharmaceutical product utilization within each key account, then maintain and grow relationships with these key decision makers within the accounts.
  • Ability to identify and procure appropriate Amgen resources to achieve account objectives.
  • Ability to analyze, interpret, and draw insights from clinic economics and financial performance.
  • Ability to analyze, interpret, and draw insights from varying data sources.
  • Ability to work in a fast-paced environment and handle multiple competing priorities.
  • Ability to work independently.
  • Broad range of computer skills.
Responsibilities
  • Serve as strategic lead for assigned key accounts, executing compliant and innovative strategies to engage priority providers whose availability requires tailored approaches.
  • Ensure institutional availability across inpatient and ambulatory care settings.
  • Lead implementation initiatives that enable sustainable institution and system utilization.
  • Develop and execute comprehensive account plans aligned to cardiovascular business unit strategy and informed by institutional needs, business performance, and identified access or implementation barriers.
  • Collaborate closely with field teams, including compliant partnership with aligned medical science liaisons as appropriate.
  • Routinely meet with appropriate opinion leaders in cardiology, lipidology, pharmacy, and Pharmacy and Therapeutics committees who act as partners or decision-makers within assigned health system manager accounts.
  • Present Medical Affairs Committee-approved data and messages and ensure compliant delivery within all governing policies.
  • Ensure targeted accounts help drive appropriate utilization of approved cardiovascular products; work with other sales colleagues to lead and coordinate pull-through and access.
  • Monitor aligned accounts, Amgen cardiovascular business performance, and overall market dynamics.
  • Identify drivers and barriers and coordinate pull-through initiatives across field teams, including sales representatives, district sales managers, regional sales directors, and reimbursement/access specialists.
  • Coordinate Amgen home office engagement with customers and work collectively with matrix and alliance team members to arrange approved programs, displays, and hospital initiatives that promote assigned products compliantly and effectively.
  • Build and develop professional relationships with key customer decision-makers, including hospital pharmacy, lipid clinical, heart failure clinical and quality directors, and hospital finance decision-makers within assigned accounts.
  • Coordinate with access specialists to support open access to the Amgen portfolio.
  • Provide field intelligence, insight, and recommendations to business analytics, brand, and market access teams.
Desired Qualifications
  • Three or more years of account management and/or public payer experience.
  • Advanced degree such as Master of Public Health, Master of Business Administration, or Doctor of Pharmacy, plus seven or more years of healthcare sales and/or marketing experience or related experience in buying processes and decision-making.
  • Clinic, hospital, dyslipidemia, heart failure, access environment, applicable competitors, and industry experience.
  • Cardiology experience, including dyslipidemia, heart failure, and acute coronary syndromes.
  • Solid understanding of the current environment and trends in community cardiology practices.
  • Understanding of internal and external dynamics in dyslipidemia and heart failure, including inpatient-to-outpatient management and protocols, readmission programs, electronic management systems, performance versus quality metrics, and congestive heart failure/interventional performance priorities.
  • District management experience.
  • Knowledge of hospital committee structure, Pharmacy and Therapeutics processes, treatment and discharge protocols, diagnosis-related group and hospital reimbursement processes for assigned accounts, and the impact on approved cardiovascular products and competitors.
  • Functional knowledge of Medicare and government agencies and the ability to match needs to strategic account management in state or federal sectors.
  • Knowledge of payer systems.
  • Knowledge of Centers for Medicare & Medicaid Services policies and processes.
  • Documented ability to work with the sales force to resolve payer-related issues.
  • Leadership ability focused on influence, impact, and leading without authority.
  • Excellent interpersonal skills, including networking, influencing, negotiation, presentation, and written and verbal communication.
  • Creative problem-solving skills.
  • Ability to take initiative, impart energy and enthusiasm, and work in teams.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 9% to $10.1 billion, with six growth drugs up 26%.
  • Repatha sales jumped 37% in Q2 2026, and Medicare-access expansion broadens prescriptions.
  • MariTide entered nine Phase 3 studies in 2026, targeting obesity, diabetes, sleep apnea, and cardiovascular disease.

What critics are saying

  • Bristol Myers and Ono sued Amgen on Sept. 15, 2026, over Opdivo biosimilar patents.
  • Britain suspended Tavneos for new patients in September 2026 after calling supporting data unreliable.
  • Prolia and XGEVA biosimilar pressure already cut Q2 2026 sales 33%, and MariTide is unproven.

What makes Amgen unique

  • Amgen’s Aug. 2026 pipeline spans Repatha, IMDELLTRA, MariTide, and olpasiran simultaneously.
  • Repatha holds primary- and secondary-prevention outcomes data, uncommon among PCSK9 competitors.
  • IMDELLTRA became an August 2026 growth engine, reaching $288 million quarterly sales.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.